

# TABLE OF CONTENTS

January 14, 2008

No. 2073

## BUSINESS

1 Industry Needs Pricing System That Rewards Innovation: JPMA President Dr Aoki

2 AstraZeneca Aims at Sales of ¥33 Bil. with Drugs for Breast Cancer in 2008

### 2 NEW PRODUCTS

- Aricept 10 mg for Severe Alzheimer's Disease: Eisai

3 Blopress Maintains No. 1 Position: Top 100 Drugs Ranking

### 6 BUSINESS NEWS IN BRIEF

- JCR Licenses JR-031 to Mochida

- Ono Licenses Drug for Thrombopenia from Nissan Chemical

- Novartis, Asahi Kasei Terminate Copromotion of Voltaren

- 2-Week Limit on Prescriptions of Preminent Lifted

- NBI to Concentrate on Marketing

- Daiichi Sankyo Reorganizes Production System for Drug Substance

- Eisai Moves Asian Business Center from Japan to Singapore

- Nippon Kayaku: Drug Sales Up 2.1% in 1st Half

- GSK to Make Major Investment in R&D Center in China

- CMIC Brazil Ties Up with Local Hospital

- Astellas Wins Patent Infringement Suit over Cefzon

- US Court Dismisses Eisai's Legal Action over Aricept on Procedural Grounds

### 8 TOPICS

- Novartis Pharma to Introduce New System to Improve MR Competence

## COMMENTARY

10 No More Need for MRs?—A Hell beyond the 2010 Crisis—: Sugio Seko

## GENERICS

13 Teva to See Its First NHI Price Listing in 2008

13 Only 16% of Consumers Ask Doctors for Generics Despite High Awareness Rate

14 Rules to Be Revised to Oblige Pharmacists to Dispense Generics: Mr Urushibata

14 *Koroshō* to Promote the Use of Generics by Welfare Recipients

## REGULATORY

15 *Koroshō*'s General Account Budget to Total ¥22,117.9 Bil.

- ¥25.6 Bil. to Promote Development of New Drugs, Medical Devices

- Social Security Spending Up 3.1% to ¥21,607.9 Bil.

- ¥23.9 Bil. for Prioritized Research

- ¥240 Mil. to Promote Use of Generics

- ¥1.8 Bil. Budget Approved for Healthcare Clusters

16 Nexavar, Licomodulin, Zevalin to Be Officially Approved Soon

16 Abnormal Behavior Reported in 38% of Patients Not Taking Tamiflu

- Abnormal Behavior Reported from 5 Patients in Current Season

17 Non-Tamiflu Users Show Higher Incidence of Abnormal Behavior: Study Team Report

- Restriction of the Use of Tamiflu in Teens to Be Continued

- Errors Found in NDA Data

- Abnormal Behavior May be Attributable to Flu Itself: Chugai

### 18 REGULATORY IN BRIEF

- FPMAJ Puzzled about Big Differences in *Yakkasa* Found in Preliminary and Final Reports

## R&D

19 GMP for Investigational Drugs to Be Amended

19 Standard Forms Completed for Clinical Trial Documents

19 Pfizer to Conduct PII Study on Glaucoma Treatment from NicOx

### 18 R&D NEWS IN BRIEF

- Japanese Gov't Should Spend 10 Times More for Science and Technology: Dr Aoki

- AIST, JBA to Create Forum on Glycotechnology

## MEDICAL DEVICE

### 20 MEDICAL DEVICE NEWS IN BRIEF

- METI to Earmark ¥10.2 Bil. to Commercialize Innovative Drugs and Medical Devices

- BCS's Autologous Cultured Skin Products Meet Guidelines: CDFS

- J&J Launches CARTO XP

### 21 ON THE MOVE

- J&J Appoints D. W. Powell President

## MEDICAL FACILITIES & NURSING CARE

22 Complete Lifting of Ban on *Kongyo Shinryo* Not Recommended by Council

22 JAPhMed to Certify Pharmaceutical Medicine Specialists

### 23 MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

- ED is a Precursor of Arteriosclerosis: Eli Lilly Japan Seminar

- Public Must Be Informed about Drug Abuse Headaches